These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 1306735)

  • 1. Prevention of local relapses and new localisations of oral leukoplakias with the synthetic retinoid fenretinide (4-HPR). Preliminary results.
    Chiesa F; Tradati N; Marazza M; Rossi N; Boracchi P; Mariani L; Clerici M; Formelli F; Barzan L; Carrassi A
    Eur J Cancer B Oral Oncol; 1992 Oct; 28B(2):97-102. PubMed ID: 1306735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fenretinide (4-HPR) in chemoprevention of oral leukoplakia.
    Chiesa F; Tradati N; Marazza M; Rossi N; Boracchi P; Mariani L; Formelli F; Giardini R; Costa A; De Palo G
    J Cell Biochem Suppl; 1993; 17F():255-61. PubMed ID: 8412202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized trial of fenretinide (4-HPR) to prevent recurrences, new localizations and carcinomas in patients operated on for oral leukoplakia: long-term results.
    Chiesa F; Tradati N; Grigolato R; Boracchi P; Biganzoli E; Crose N; Cavadini E; Formelli F; Costa L; Giardini R; Zurrida S; Costa A; De Palo G; Veronesi U
    Int J Cancer; 2005 Jul; 115(4):625-9. PubMed ID: 15700313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fenretinide breast cancer prevention trial: drug and retinol plasma levels in relation to age and disease outcome.
    Formelli F; Camerini T; Cavadini E; Appierto V; Villani MG; Costa A; De Palo G; Di Mauro MG; Veronesi U
    Cancer Epidemiol Biomarkers Prev; 2003 Jan; 12(1):34-41. PubMed ID: 12540501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful topical treatment of oral lichen planus and leukoplakias with fenretinide (4-HPR).
    Tradati N; Chiesa F; Rossi N; Grigolato R; Formelli F; Costa A; de Palo G
    Cancer Lett; 1994 Jan; 76(2-3):109-11. PubMed ID: 8149338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Controlled clinical trials with fenretinide in breast cancer, basal cell carcinoma and oral leukoplakia.
    De Palo G; Veronesi U; Marubini E; Camerini T; Chiesa F; Nava M; Formelli F; Del Vecchio M; Costa A; Boracchi P
    J Cell Biochem Suppl; 1995; 22():11-7. PubMed ID: 8538187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Breast tissue accumulation of retinamides in a randomized short-term study of fenretinide.
    Sabichi AL; Modiano MR; Lee JJ; Peng YM; Xu MJ; Villar H; Dalton WS; Lippman SM
    Clin Cancer Res; 2003 Jul; 9(7):2400-5. PubMed ID: 12855611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mammographic patterns in breast cancer chemoprevention with fenretinide (4-HPR).
    Cassano E; Coopmans de Yoldi G; Ferranti C; Costa A; Mascotti G; De Palo G; Veronesi U
    Eur J Cancer; 1993; 29A(15):2161-3. PubMed ID: 8297658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The synthetic retinoid fenretinide lowers plasma insulin-like growth factor I levels in breast cancer patients.
    Torrisi R; Pensa F; Orengo MA; Catsafados E; Ponzani P; Boccardo F; Costa A; Decensi A
    Cancer Res; 1993 Oct; 53(20):4769-71. PubMed ID: 8402658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fenretinide activity in retinoid-resistant oral leukoplakia.
    Lippman SM; Lee JJ; Martin JW; El-Naggar AK; Xu X; Shin DM; Thomas M; Mao L; Fritsche HA; Zhou X; Papadimitrakopoulou V; Khuri FR; Tran H; Clayman GL; Hittelman WN; Hong WK; Lotan R
    Clin Cancer Res; 2006 May; 12(10):3109-14. PubMed ID: 16707609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tolerability of the synthetic retinoid Fenretinide (HPR).
    Costa A; Malone W; Perloff M; Buranelli F; Campa T; Dossena G; Magni A; Pizzichetta M; Andreoli C; Del Vecchio M
    Eur J Cancer Clin Oncol; 1989 May; 25(5):805-8. PubMed ID: 2525470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemoprevention trial of contralateral breast cancer with fenretinide. Rationale, design, methodology, organization, data management, statistics and accrual.
    De Palo G; Camerini T; Marubini E; Costa A; Formelli F; Del Vecchio M; Mariani L; Miceli R; Mascotti G; Magni A; Campa T; Di Mauro MG; Attili A; Maltoni C; Del Turco MR; Decensi A; D'Aiuto G; Veronesi U
    Tumori; 1997; 83(6):884-94. PubMed ID: 9526578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I-II preoperative biomarker trial of fenretinide in ascitic ovarian cancer.
    Colombo N; Formelli F; Cantù MG; Parma G; Gasco M; Argusti A; Santinelli A; Montironi R; Cavadini E; Baglietto L; Guerrieri-Gonzaga A; Viale G; Decensi A
    Cancer Epidemiol Biomarkers Prev; 2006 Oct; 15(10):1914-9. PubMed ID: 17035399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospects of chemoprevention of human cancers with the synthetic retinoid fenretinide.
    Costa A; Formelli F; Chiesa F; Decensi A; De Palo G; Veronesi U
    Cancer Res; 1994 Apr; 54(7 Suppl):2032s-2037s. PubMed ID: 8137334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Follow-up of oral leukoplakia after carbon dioxide laser surgery.
    Chiesa F; Tradati N; Sala L; Costa L; Podrecca S; Boracchi P; Bandieramonte G; Mauri M; Molinari R
    Arch Otolaryngol Head Neck Surg; 1990 Feb; 116(2):177-80. PubMed ID: 2297409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved oral delivery of N-(4-hydroxyphenyl)retinamide with a novel LYM-X-SORB organized lipid complex.
    Maurer BJ; Kalous O; Yesair DW; Wu X; Janeba J; Maldonado V; Khankaldyyan V; Frgala T; Sun BC; McKee RT; Burgess SW; Shaw WA; Reynolds CP
    Clin Cancer Res; 2007 May; 13(10):3079-86. PubMed ID: 17505011
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activity of 4-HPR in superficial bladder cancer using DNA flow cytometry as an intermediate endpoint.
    Decensi A; Bruno S; Giaretti W; Torrisi R; Curotto A; Gatteschi B; Geido E; Polizzi A; Costantini M; Bruzzi P
    J Cell Biochem Suppl; 1992; 16I():139-47. PubMed ID: 1305678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pilot trial of the safety, tolerability, and retinoid levels of N-(4-hydroxyphenyl) retinamide in combination with tamoxifen in patients at high risk for developing invasive breast cancer.
    Conley B; O'Shaughnessy J; Prindiville S; Lawrence J; Chow C; Jones E; Merino MJ; Kaiser-Kupfer MI; Caruso RC; Podgor M; Goldspiel B; Venzon D; Danforth D; Wu S; Noone M; Goldstein J; Cowan KH; Zujewski J
    J Clin Oncol; 2000 Jan; 18(2):275-83. PubMed ID: 10637240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibitory effects of fenretinide metabolites N-[4-methoxyphenyl]retinamide (MPR) and 4-oxo-N-(4-hydroxyphenyl)retinamide (3-keto-HPR) on fenretinide molecular targets β-carotene oxygenase 1, stearoyl-CoA desaturase 1 and dihydroceramide Δ4-desaturase 1.
    Poliakov E; Samuel W; Duncan T; Gutierrez DB; Mata NL; Redmond TM
    PLoS One; 2017; 12(4):e0176487. PubMed ID: 28448568
    [TBL] [Abstract][Full Text] [Related]  

  • 20. N-(4-hydroxyphenyl)retinamide in the chemoprevention of squamous metaplasia and dysplasia of the bronchial epithelium.
    Kurie JM; Lee JS; Khuri FR; Mao L; Morice RC; Lee JJ; Walsh GL; Broxson A; Lippman SM; Ro JY; Kemp BL; Liu D; Fritsche HA; Xu X; Lotan R; Hong WK
    Clin Cancer Res; 2000 Aug; 6(8):2973-9. PubMed ID: 10955773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.